235 related articles for article (PubMed ID: 18319488)
1. Diabetes specialists keep ACCORD data in perspective.
Traynor K
Am J Health Syst Pharm; 2008 Mar; 65(6):488, 490. PubMed ID: 18319488
[No Abstract] [Full Text] [Related]
2. A summary of the ADVANCE Trial.
Heller SR;
Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S357-61. PubMed ID: 19875581
[No Abstract] [Full Text] [Related]
3. Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?
Lipska KJ; Krumholz HM
JAMA; 2017 Mar; 317(10):1017-1018. PubMed ID: 28125758
[No Abstract] [Full Text] [Related]
4. Type 2 diabetes: target HbA1c of about 7%.
Prescrire Int; 2009 Aug; 18(102):177. PubMed ID: 19746575
[TBL] [Abstract][Full Text] [Related]
5. Case study 1: exploring the pharmacologic agents for treatment of type 2 diabetes.
Martin CL
Diabetes Educ; 2007; 33 Suppl 1():6S-13S. PubMed ID: 17272803
[No Abstract] [Full Text] [Related]
6. United Kingdom prospective diabetes study: a different perspective.
Kabadi UM
Endocr Pract; 2002; 8(1):61-4. PubMed ID: 11939763
[No Abstract] [Full Text] [Related]
7. [Different strategies in prediabetes, new and long-time diabetes. What therapy for what diabetics?].
Stiefelhagen P
MMW Fortschr Med; 2010 Jan; 152(3):12-4, 16. PubMed ID: 20333958
[No Abstract] [Full Text] [Related]
8. [Tough glucose reduction necessary in newly diagnosed diabetes].
Rydén M
Lakartidningen; 2010 Nov 10-16; 107(45):2810-4. PubMed ID: 21179867
[No Abstract] [Full Text] [Related]
9. Should we use intensive insulin therapy after oral agent failure in type II diabetes?
Colwell JA
Diabetes Care; 1996 Aug; 19(8):896-8. PubMed ID: 8842613
[No Abstract] [Full Text] [Related]
10. Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence?
Boussageon R; Gueyffier F; Cornu C
Diabetes Metab; 2014 Jun; 40(3):169-75. PubMed ID: 24503191
[TBL] [Abstract][Full Text] [Related]
11. Glyburide/metformin HCl clinical overview.
Seymour A
Manag Care; 2001 Feb; 10(2 Suppl):11-6. PubMed ID: 11729403
[No Abstract] [Full Text] [Related]
12. [Aggressive and early combined drug therapy. Antidiabetics for prevention of myocardial infarct].
MMW Fortschr Med; 2003 Jun; 145(25):52. PubMed ID: 12891856
[No Abstract] [Full Text] [Related]
13. Intensive glycemic control: implications of the accord, advance, and VADT trials for family physicians.
Dhar GC
Can Fam Physician; 2009 Aug; 55(8):803-4. PubMed ID: 19675265
[No Abstract] [Full Text] [Related]
14. Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor.
Riddle MC
Diabetes Care; 2008 Feb; 31 Suppl 2():S125-30. PubMed ID: 18227472
[No Abstract] [Full Text] [Related]
15. Tight glycaemic control and cardiovascular disease in type 2 diabetes.
Demssie YN; Soran H; Younis N
Br J Hosp Med (Lond); 2009 Jan; 70(1):31-2, 34. PubMed ID: 19357575
[TBL] [Abstract][Full Text] [Related]
16. Type 2 diabetes and HbA1c targets.
Prescrire Int; 2008 Dec; 17(98):254. PubMed ID: 19425272
[TBL] [Abstract][Full Text] [Related]
17. Options for intensifying diabetes treatment.
Reid TS
J Fam Pract; 2011 Sep; 60(9 Suppl):S7-10. PubMed ID: 21912777
[No Abstract] [Full Text] [Related]
18. [Certain beginning of insulin therapy: yes, we can, but...].
Rohrer A
Praxis (Bern 1994); 2009 Mar; 98(6):301. PubMed ID: 19338117
[No Abstract] [Full Text] [Related]
19. Safety of very tight glucose control in type 2 diabetes in question.
Idris I
Diabetes Obes Metab; 2008 May; 10(5):438. PubMed ID: 18431839
[No Abstract] [Full Text] [Related]
20. Importance of glycemic control.
Shahady EJ
J Fam Pract; 2011 Sep; 60(9 Suppl):S4-6. PubMed ID: 21912776
[No Abstract] [Full Text] [Related]
[Next] [New Search]
